Mogrify® has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
Leveraging data from next-generation sequencing and regulatory networks (DNA-protein & protein-protein), the platform takes a systematic big-data approach to identify the transcription factors (in vitro) or small molecules (in vivo), needed to convert, maintain and culture a target cell phenotype.
Mogrify can perform cell conversions from any starting cell type giving it the best opportunity to address challenges associated with efficacy, safety and scalability that currently mean cell therapy is underperforming its undoubted potential.
Mogrify is applying its patented technology through therapeutic development as well as licensing of proprietary cell conversions that will power the development and manufacture of new cell therapies across every therapeutic area.
Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised over $20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.
Dr. Jane Osbourn OBE
Jane has over 30 years of experience in biologics discovery and development. Most recently, she was Vice President for R&D and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology.
Jane is a scientific leader in the field of antibody engineering, and has made a significant contribution to the discovery and development of 8 marketed drugs and over 40 clinical candidates. Jane is passionate about science education and the development of the UK biotech sector and has served as Chair of the Board of Directors of the BioIndustry Association for the past four years. She is currently a Director of Babraham Bioscience Technologies, and also a Director of Cambridge Enterprise. She was awarded Scrip’s Lifetime Achievement Award and an OBE in 2019 for services to drug discovery, development and biotechnology.
Dr. Darrin M. Disley OBE
Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown or invested in over 40 start-up life science, technology and social enterprises, raising $525 million USD in business financing and closing $600 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was awarded a lifetime Queens Award for Enterprise Promotion in 2016 for his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.
Dr. Karin Schmitt
Karin has over 25 years’ experience with a sustained track record of successful leadership roles within the life sciences, biotech and therapeutic industries at Exelixis, Inc., Millennium Pharmaceuticals, Thermo Fisher Scientific, Horizon Discovery Group plc and PredictImmune Ltd. Karin has brought over 20 innovative products to market internationally, across a wide scientific spectrum, with recent emphasis on clinical products and has additional experience in legal, commercial and regulatory pathways. Karin obtained her PhD in molecular biology at the University of Southern California in Los Angeles, followed by three years of post-doctoral research in genetics at the University of Cambridge.
Joe began his career at Horizon Discovery Group plc working within the corporate development team gaining experience in business planning, licensing, technology evaluation and M&A analysis, before becoming Dr. Jonathan Milner’s (Co-founder of Abcam plc) Portfolio Manager where he built and managed a complex portfolio of more than 40 early-stage life science companies. Joe holds a degree in molecular and cellular biology from the University of Bath and an MPhil in business management from the University of Cambridge.
Prof. Julian Gough
Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.
Corporate Development Executive
Pierre-Louis has a background in Biochemistry and Pharmacology from the University of St Andrews and the University of Oxford. He previously worked in early stage venture development and investment at Oxford Sciences Innovations (OSI) and Deep Science Ventures (DSV) before becoming the first employee at Mogrify.
Prof. Owen Rackham
Owen is world expert in the application of machine learning and complex systems in cell reprograming. He was a career development fellow at the Medical Research Council, UK and was the recipient of a JSPS fellowship to work at the RIKEN Omics Science Centre in Yokohama. He is now an Assistant Professor at the Duke-NUS Medical School in Singapore.
Prof. Jose Polo
Jose has worked at the cutting-edge of cell reprograming for over a decade. He graduated his PhD at the Albert Einstein College of Medicine in New York before becoming a research fellow at the Harvard Stem Cell Institute. He was awarded a NHMRC career development fellowship, a Charles Viertel Senior Medical Research fellowship as well as an ARC future fellowship and is now a Professor at Monash University.
RIKEN scientists launch international consortium to provide insight into the regulatory landscape of the transcriptome across as many cell states as possible.
Collaboration with co-founder Jose Polo to test cell conversions begins and three new conversions are validated with the V1 platform in just several months.
$3.7M seed capital raised, appoints Dr. Darrin M. Disley, OBE as CEO, launch of Mogrify V2 and Epimogrify V1 platforms, hiring up to 40 scientists and raising an additional $16 million USD in the initial close of its Series A funding. Dr. Jane Osbourn, OBE appointed as Chair.
Julian Gough and Owen Rackham begin the V1 platform development using the unpublished FANTOM 5 consortium data.
Julian Gough, Owen Rackham, Jose Polo file a PCT patent for the V1 platform and over 30 direct cell conversions.
Mogrify Ltd incorporated with pre-seed and grant funding to begin the industrial development and application of the V1 platform.
MSD’s Innovation Award 2019
The Innovation Award at Scrip recognizes the significant potential the Company’s direct cellular conversion technology has to disrupt the future development of new medicines.
Disruptive Technology Award 2019
The ‘Disruptive Technology’ category at the Business Weekly Awards, recognises the Company’s novel bioinformatic platform, which is built upon a decade of world-class multidisciplinary science.
Seed Stage Finance Raise of the Year 2019
Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organizations that play such a critical role in the advancement of the industry across Europe.
Named ‘The One to Watch’ 2019
Recognizing the potential of the Company’s proprietary direct cellular conversion technology, enabling any mature adult cell to be transformed into any other, without going through a pluripotent stem cell-state.